Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Ambrx, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Ambrx, Inc. - Product Pipeline Review - 2014', provides an overview of the Ambrx, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Ambrx, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Ambrx, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Ambrx, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Ambrx, Inc.'s pipeline products Reasons to buy - Evaluate Ambrx, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Ambrx, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Ambrx, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Ambrx, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ambrx, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Ambrx, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Ambrx, Inc. Snapshot 5 Ambrx, Inc. Overview 5 Key Information 5 Key Facts 5 Ambrx, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Ambrx, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Ambrx, Inc. - Pipeline Products Glance 15 Ambrx, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Ambrx, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Ambrx, Inc. - Drug Profiles 18 ARX-201 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ARX-328 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ARX-788 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 insulin human 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibody Conjugated for Inflammation 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibody Drug Conjugate to Target CD70 for Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Alpha CD3-Folate 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Alpha PSMA-ADC 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody Drug Conjugates for Undisclosed Indication 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Ambrx, Inc. - Pipeline Analysis 27 Ambrx, Inc. - Pipeline Products by Target 27 Ambrx, Inc. - Pipeline Products by Route of Administration 28 Ambrx, Inc. - Pipeline Products by Molecule Type 29 Ambrx, Inc. - Pipeline Products by Mechanism of Action 30 Ambrx, Inc. - Dormant Projects 31 Ambrx, Inc. - Locations And Subsidiaries 32 Head Office 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 34 Disclaimer 34
List of Tables Ambrx, Inc., Key Information 5 Ambrx, Inc., Key Facts 5 Ambrx, Inc. - Pipeline by Indication, 2014 8 Ambrx, Inc. - Pipeline by Stage of Development, 2014 9 Ambrx, Inc. - Monotherapy Products in Pipeline, 2014 10 Ambrx, Inc. - Partnered Products in Pipeline, 2014 11 Ambrx, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Ambrx, Inc. - Out-Licensed Products in Pipeline, 2014 13 Ambrx, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Ambrx, Inc. - Phase II, 2014 15 Ambrx, Inc. - Preclinical, 2014 16 Ambrx, Inc. - Discovery, 2014 17 Ambrx, Inc. - Pipeline by Target, 2014 27 Ambrx, Inc. - Pipeline by Route of Administration, 2014 28 Ambrx, Inc. - Pipeline by Molecule Type, 2014 29 Ambrx, Inc. - Pipeline Products by Mechanism of Action, 2014 30 Ambrx, Inc. - Dormant Developmental Projects,2014 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.